Sound View Wealth Advisors Group LLC Boosts Position in Stryker Co. (NYSE:SYK)

Sound View Wealth Advisors Group LLC raised its holdings in Stryker Co. (NYSE:SYK - Free Report) by 63.0% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 8,026 shares of the medical technology company's stock after purchasing an additional 3,102 shares during the quarter. Sound View Wealth Advisors Group LLC's holdings in Stryker were worth $2,890,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently bought and sold shares of the company. Principal Financial Group Inc. lifted its position in shares of Stryker by 6.2% during the 3rd quarter. Principal Financial Group Inc. now owns 398,422 shares of the medical technology company's stock valued at $143,934,000 after buying an additional 23,329 shares during the last quarter. Kornitzer Capital Management Inc. KS lifted its position in shares of Stryker by 1.9% during the 3rd quarter. Kornitzer Capital Management Inc. KS now owns 8,084 shares of the medical technology company's stock valued at $2,920,000 after buying an additional 152 shares during the last quarter. Portside Wealth Group LLC purchased a new position in shares of Stryker during the 3rd quarter valued at $215,000. Fiera Capital Corp lifted its position in shares of Stryker by 11.8% during the 3rd quarter. Fiera Capital Corp now owns 18,682 shares of the medical technology company's stock valued at $6,749,000 after buying an additional 1,969 shares during the last quarter. Finally, Leavell Investment Management Inc. lifted its position in shares of Stryker by 24.4% during the 3rd quarter. Leavell Investment Management Inc. now owns 1,111 shares of the medical technology company's stock valued at $402,000 after buying an additional 218 shares during the last quarter. Institutional investors own 77.09% of the company's stock.

Remove Ads

Stryker Price Performance

Shares of NYSE SYK traded down $1.77 during trading hours on Wednesday, reaching $363.52. 1,559,119 shares of the stock traded hands, compared to its average volume of 1,218,285. The company has a market capitalization of $138.71 billion, a P/E ratio of 46.85, a price-to-earnings-growth ratio of 2.93 and a beta of 0.95. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59. Stryker Co. has a 52-week low of $314.93 and a 52-week high of $406.19. The company's 50-day simple moving average is $382.76 and its two-hundred day simple moving average is $373.33.

Stryker (NYSE:SYK - Get Free Report) last announced its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, beating analysts' consensus estimates of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same quarter in the previous year, the business posted $3.46 EPS. Equities research analysts forecast that Stryker Co. will post 13.47 EPS for the current year.

Stryker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be paid a $0.84 dividend. The ex-dividend date of this dividend is Monday, March 31st. This represents a $3.36 dividend on an annualized basis and a yield of 0.92%. Stryker's dividend payout ratio (DPR) is currently 43.30%.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on SYK. Needham & Company LLC reissued a "buy" rating and set a $442.00 price objective on shares of Stryker in a report on Wednesday, January 29th. Wells Fargo & Company increased their price objective on Stryker from $427.00 to $435.00 and gave the stock an "overweight" rating in a report on Wednesday, January 29th. JMP Securities reissued a "market perform" rating on shares of Stryker in a report on Tuesday, February 18th. JPMorgan Chase & Co. increased their price objective on Stryker from $420.00 to $445.00 and gave the stock an "overweight" rating in a report on Wednesday, January 29th. Finally, Argus set a $450.00 price objective on Stryker in a report on Monday, February 3rd. Five equities research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $421.90.

Insiders Place Their Bets

In other Stryker news, Director Allan C. Golston sold 2,458 shares of Stryker stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total value of $941,586.06. Following the transaction, the director now directly owns 14,895 shares of the company's stock, valued at $5,705,827.65. The trade was a 14.16 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Ronda E. Stryker sold 201,392 shares of Stryker stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $392.24, for a total value of $78,993,998.08. Following the completion of the transaction, the director now directly owns 3,642,075 shares in the company, valued at $1,428,567,498. This trade represents a 5.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 5.90% of the company's stock.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.